Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion B shares owned directly, indirectly or through financial instruments by BlackRock, Inc. and its funds increased on 3 May 2021 above five (5) per cent of Orion Corporation’s total shares.
Total positions of BlackRock, Inc. and its funds subject to notification:
| % of shares and voting rights (total of point A) | % of shares and voting rights through financial instruments (total of point B) | Total of both in % (points A + B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 4.85% shares Below 5% voting rights | 0.15% shares Below 5% voting rights | 5.00% shares Below 5% voting rights | 141,134,278 shares In BlackRock’s disclosure: 814,560,303 votes Orion’s correction: 806,883,011 votes |
| Position of previous notification (if applicable) | N/A | N/A | N/A |
Notified details of the resulting situation on the date on which the threshold was crossed:
Point A: Shares and voting rights:
| Class/type of shares ISIN code | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI0009014377 | 6,856,653 shares Below 5% voting rights | 4.85% shares Below 5% voting rights | ||
| POINT A SUBTOTAL | 6,856,653 shares Below 5% voting rights | 4.85% shares Below 5% voting rights | ||
Point B: Financial instruments according to SMA 9:6a:
| Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
| Securities Lent | N/A | N/A | Physical | 171,060 shares Below 5% voting rights | 0.12% shares Below 5% voting rights |
| CFD | N/A | N/A | Cash | 42,719 shares Below 5% voting rights | 0.03 % shares Below 5% voting rights |
| POINT B SUBTOTAL | 213,779 shares Below 5% voting rights | 0.15 % shares Below 5% voting rights |
Orion Corporation
| Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.